Your session is about to expire
← Back to Search
Benralizumab for Bronchiectasis (MAHALE Trial)
MAHALE Trial Summary
This trial is testing if a drug called benralizumab can help reduce exacerbation rates for people with non-cystic fibrosis bronchiectasis who also have eosinophilic inflammation. The trial will last for 52 weeks, and patients who complete the trial will be eligible for an extension where they will receive the drug for at least one more year.
MAHALE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMAHALE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 220 Patients • NCT02075255MAHALE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any previous case studies of patients being treated with Benralizumab?
"Out of the 20 ongoing studies on Benralizumab, 10 are currently in Phase 3. The majority of these studies are situated in Bethesda, Maryland; however, there are 1,481 total clinical trial sites for this medication."
Are we looking for test subjects who are over the age of 35 for this experiment?
"The acceptable age range for participants in this trial is between 18 and 130 years old."
What have been the most serious side effects associated with Benralizumab?
"Benralizumab is in Phase 3 of clinical trials, which implies that there is some data affirming its efficacy and multiple rounds of data affirming its safety--our team at Power rated it a 3 on a scale from 1 to 3."
What is the largest number of people who can sign up for this research project?
"Unfortunately, this trial is not presently looking for new candidates. The study was originally posted on 7/21/2021 but was most recently edited on 8/24/2022. For patients looking for other studies, 438 trials actively enrolling patients with bronchiectasis and 20 trials for Benralizumab are searching for participants."
Does this research mark a new era in this field of study?
"Benralizumab was first studied in 2014 with Phase 2 & 3 approval coming later. Currently, there are 20 active studies being conducted in 352 cities across 42 countries."
Could you tell me how many hospitals are participating in this trial at the moment?
"Enrollment for this clinical trial is currently open at 18 sites, which are situated in Newport Beach, Washington, Statesville, and other cities. To reduce the burden of travel, patients are encouraged to enroll at the location nearest to them."
What are the requirements for subjects in this clinical trial?
"This study is seeking 79 individuals, aged 18 to 130, who have bronchiectasis and are currently receiving airway clearance therapy, physiotherapy, or mucus clearance therapy. The dose and regimen of these therapies and any drugs used to aid expectoration must be stable for at least 3 months prior to the screening visit and remain stable throughout the study. Male or female patients who meet the following criteria are eligible for inclusion: a documented history of 2 or more bronchiectasis exacerbations within a year of the screening visit, no recent prophylactic antibiotic use (if prophylactic macrolides have been recently"
Can people with the disease still sign up to participate in the research?
"This clinical trial is not presently searching for candidates anymore. The trial was initially posted on 7/21/2021 and was last updated on 8/24/2022. If you are seeking for other studies, there are currently 438 trials actively looking for participants with bronchiectasis and 20 studies for Benralizumab actively enrolling participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger